Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Uncovering the novel role of intra-tumoral regulatory innate lymphoid cells in immune tolerance

FY 2017-18

Summary
High grade serous ovarian carcinoma (HGSOC) makes up the majority of patients with ovarian cancer, and has the lowest survival rates compared to other subtypes of ovarian cancer. Women with HGSOC generally have a poor prognosis, and majority of these patients relapse within half a year in response to current good-standard therapies, including surgery and chemotherapy. Immunotherapy is gaining a lot attention for scientists, physicians, and patients alike. Despite the tremendous success of boosting our immune system to selectively kill tumour cells, a large portion of patients are unresponsive to these immunotherapies. One of the reasons for a high proportion of non-responders is because tumours often have suppressors cells shuts down the immune anti-tumour response. Our group was the first to show a new population of suppressors cells, called regulatory innate lymphoid cells (ILCregs), that existed in the tumour collected from patients with HGSOC. This project aims to further investigate the role of ILCregs in suppressing the anti-tumour immune response in HGSOC. Using single-cell molecular techniques, we will be able to molecularly characterize these ILCregs and determine whether they may act as predictors for clinical outcomes of patients. Furthermore, we hope to discover new biomarkers that distinguishes ILCregs from other immune cells to aid in therapeutic targeting of these suppressor cells. By understanding how these cells suppress the immune system, and through biomarker discovery, we may be able to therapeutically target ILCregs to enhance the efficacy of cancer immunotherapy.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
386362
Name
Chung Douglas C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Uncovering the novel role of intra-tumoral regulatory innate lymphoid cells in immune tolerance
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Immunotherapy; Immune Suppression; Innate Lymphoid Cells; Mass Cytometry; Natural Killer Cells; Ovarian Carcinoma; Single Cell Sequencing; T Cell Exhaustion; T Lymphocytes; Tumour Microenvironment
Abstract
High grade serous ovarian carcinoma (HGSOC) makes up the majority of patients with ovarian cancer, and has the lowest survival rates compared to other subtypes of ovarian cancer. Women with HGSOC generally have a poor prognosis, and majority of these patients relapse within half a year in response to current good-standard therapies, including surgery and chemotherapy. Immunotherapy is gaining a lot attention for scientists, physicians, and patients alike. Despite the tremendous success of boosting our immune system to selectively kill tumour cells, a large portion of patients are unresponsive to these immunotherapies. One of the reasons for a high proportion of non-responders is because tumours often have suppressors cells shuts down the immune anti-tumour response. Our group was the first to show a new population of suppressors cells, called regulatory innate lymphoid cells (ILCregs), that existed in the tumour collected from patients with HGSOC. This project aims to further investigate the role of ILCregs in suppressing the anti-tumour immune response in HGSOC. Using single-cell molecular techniques, we will be able to molecularly characterize these ILCregs and determine whether they may act as predictors for clinical outcomes of patients. Furthermore, we hope to discover new biomarkers that distinguishes ILCregs from other immune cells to aid in therapeutic targeting of these suppressor cells. By understanding how these cells suppress the immune system, and through biomarker discovery, we may be able to therapeutically target ILCregs to enhance the efficacy of cancer immunotherapy.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chung, Douglas C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~